 |
 |
PharmaVOICE - June 2009 Meet the Chief Scientific Officers By Denise Myshko Chief scientific officers help translate the company’s science into understandable concepts for investors, partners, and other stakeholders. The chief scientist officer helps set a company’s strategy, interacts with investors and board of directors, and helps people understand the science behind new products. Sidebars Sound Bites from the Field Karla Anderson, Managing Director of the Life Sciences Practice, BearingPoint Inc. For more information, visit bearingpoint.com. Nancy Dreyer, Ph.D., Chief of Scientific Affairs and Senior VP, Outcome. For more information, visit outcome.com. S. Yin Ho, M.D., VP, Corporate Strategy, Medidata. For more information, visit mdsol.com. Colin G. Miller, Ph.D., Senior VP, Medical Affairs, BioClinica. For more information, visit bioclinica.com. Linda Patricia Miller, M.D., VP, Clinical Development, and Chief Scientific Officer, Clinsys Clinical Research Inc. For more information, visit clinsys.com. Peter Werth, CEO of ChemWerth Inc., a full-service generic API development, and supply company specializing in oral, injectable, topical, and veterinary products. For more information, visit chemwerth.com. Thought Leaders Julian Adams, Ph.D. President of R&D and Chief Scientific Officer, Infinity Pharmaceuticals Inc., a cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. For more information, visit infi.com. Joseph B. Bolen, Ph.D. Chief Scientific Officer, Millennium: The Takeda Oncology Company, a biopharmaceutical company whose research, development, and commercialization activities are focused in oncology. For more information, visit millennium.com. Charles R. Cantor, Ph.D. Chief Scientific Officer, Sequenom Inc., which provides genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research, and molecular medicine applications. For more information, visit sequenom.com. Timothy P. Clackson, Ph.D. Senior VP and Chief Scientific Officer, Ariad Pharmaceuticals Inc., whose mission is to discover, develop, and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need: aggressive cancers for which current therapies are inadequate. For more information, visit ariad.com. Kevin Judice, Ph.D. CEO and Chief Scientific Officer, Achaogen Inc., a clinical-stage biopharmaceutical company addressing the issue of multidrug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics. For more information, visit achaogen.com. Ruth McKernan, Ph.D. Chief Scientific Officer and Head of Pfizer Regenerative Medicine, Pfizer Inc., a biopharmaceutical company that discovers, develops, manufactures, and delivers quality, safe, and effective prescription medicines to treat and help prevent disease for both people and animals. For more information, visit pfizer.com. Martin Petkovich, Ph.D. Chief Scientific Officer and Co-founder, Cytochroma Inc., a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). For more information, visit cytochroma.com. Barry Polisky, Ph.D. Chief Scientific Officer, MDRNA Inc., a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). For more information, visit mdrnainc.com. Jasbir Seehra, Ph.D. Chief Scientific Officer, Senior VP and Founder, Acceleron Pharma Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle, and red blood cells. For more information, visit acceleronpharma.com. Marc Tessier-Lavigne, Ph.D. Executive VP of Research and Chief Scientific Officer, Genentech Inc., a wholly owned member of the Roche Group, is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. For more information, visit gene.com.
|
